Table II.

Efficacy in early breast cancer trastuzumab studies

		bcirg006
	nsabpB31,ncctgN9831a	ac → th	tch	hera
Regimen	Concurrent	Concurrent		Sequential
Follow-up	2 Years	2 Years		1 Year
Evaluable patients (n)	3351	3222		3387
Hazard ratios
dfs	0.48 2p=3×10−12	0.49 p<0.0001	0.61 p=0.0002	0.54 p<0.0001
ddfs	0.47 2p=8×10−10	NR	NR	0.51 p<0.0001
os	0.67 2p=0.015	NR	NR	0.76 p=0.26

^aCombined analysis.

nsabp = National Surgical Adjuvant Breast and Bowel Project; ncctg = North Central Cancer Treatment Group; bcirg = Breast Cancer International Research Group; hera = Herceptin Adjuvant Trial; ac → th = doxorubicin–cyclophosphamide/docetaxel–trastuzumab; tch = docetaxel–carboplatin–trastuzumab; dfs = disease-free survival; ddfs = distant dfs; os = overall survival.